^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Synovial Sarcoma

Phase 1/2
Roswell Park Cancer Institute
Active, not recruiting
Last update posted :
06/13/2024
Initiation :
07/14/2017
Primary completion :
03/04/2021
Completion :
07/14/2032
BRAF • CTAG1B
|
BRAF mutation
|
azacitidine • cyclophosphamide • decitabine • cyclophosphamide intravenous
Phase 1
Sapience Therapeutics
Recruiting
Last update posted :
06/05/2024
Initiation :
06/05/2023
Primary completion :
05/31/2026
Completion :
05/31/2027
PD-L1 • MSI • BRCA
|
PD-L1 expression • MSI-H/dMMR • BRCA mutation
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium • ST316
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
06/04/2024
Initiation :
03/27/2024
Primary completion :
11/30/2026
Completion :
11/30/2028
HLA-A • CTAG1B • SSX1
|
HLA-A*02
|
cyclophosphamide • fludarabine IV
Phase 2
Epizyme, Inc.
Completed
Last update posted :
04/29/2024
Initiation :
12/22/2015
Primary completion :
02/26/2024
Completion :
02/26/2024
CD34 • SS18
|
SMARCA4 mutation
|
Tazverik (tazemetostat)
Phase 1/2
Adaptimmune
Recruiting
Last update posted :
04/24/2024
Initiation :
09/01/2023
Primary completion :
10/01/2026
Completion :
07/30/2038
HLA-A • MAGEA4
|
HLA-A*02 • HLA-A2 positive • MAGEA4 expression
|
Tecelra (afamitresgene autoleucel)
Phase 1
Seattle Children's Hospital
Active, not recruiting
Last update posted :
04/23/2024
Initiation :
07/13/2020
Primary completion :
12/01/2025
Completion :
12/01/2040
CD276
|
CD276 expression • CD19 expression
|
Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
Phase 1
Seattle Children's Hospital
Recruiting
Last update posted :
04/09/2024
Initiation :
06/18/2019
Primary completion :
06/01/2025
Completion :
06/01/2040
EGFR
|
EGFR expression
|
EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
Phase 2
Adaptimmune
Recruiting
Last update posted :
02/19/2024
Initiation :
08/13/2019
Primary completion :
10/10/2021
Completion :
04/01/2038
HLA-A • MAGEA4
|
HLA-A*02 • MAGEA4 expression
|
Tecelra (afamitresgene autoleucel)
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
01/25/2024
Initiation :
12/07/2021
Primary completion :
12/31/2027
Completion :
12/31/2040
HER-2
|
HER-2 positive • HER-2 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
Phase 1
Adaptimmune
Active, not recruiting
Last update posted :
01/22/2024
Initiation :
05/15/2017
Primary completion :
12/27/2022
Completion :
09/01/2032
HLA-A • MAGEA4
|
HLA-A*02 • HLA-A2 positive
|
Tecelra (afamitresgene autoleucel)
Phase 1
Valo Therapeutics Oy
Recruiting
Last update posted :
01/12/2024
Initiation :
02/02/2023
Primary completion :
06/01/2025
Completion :
09/01/2025
PD-L1
|
Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1
Phase 1
University Health Network, Toronto
Active, not recruiting
Last update posted :
12/08/2023
Initiation :
09/01/2016
Primary completion :
09/01/2024
Completion :
09/01/2024
HLA-A • CTAG1B
|
HLA-A*02 • CTAG1B expression
|
cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous
Phase 1/2
Takara Bio Inc.
Completed
Last update posted :
12/06/2023
Initiation :
09/20/2017
Primary completion :
01/23/2020
Completion :
03/09/2022
HLA-A • CTAG1B
|
HLA-A*02 • CTAG1B expression
|
cyclophosphamide • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous
Phase 1/2
University Hospital Tuebingen
Recruiting
Last update posted :
11/22/2023
Initiation :
09/19/2023
Primary completion :
06/01/2027
Completion :
09/01/2027
CD8 • CD4
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
10/25/2023
Initiation :
12/14/2017
Primary completion :
04/08/2021
Completion :
03/14/2023
IFNG • CTAG1B
|
CTAG1B expression
|
Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)
Phase 2
GlaxoSmithKline
Active, not recruiting
Last update posted :
10/16/2023
Initiation :
12/31/2019
Primary completion :
10/12/2022
Completion :
07/01/2024
HLA-A • CTAG1B
|
HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
|
cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
Phase 1
M.D. Anderson Cancer Center
Completed
Last update posted :
10/16/2023
Initiation :
09/13/2018
Primary completion :
12/06/2022
Completion :
12/06/2022
HLA-A • CTAG1B
|
cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous
Phase 1b
OHSU Knight Cancer Institute
Completed
Last update posted :
08/16/2023
Initiation :
03/10/2017
Primary completion :
10/08/2019
Completion :
06/30/2023
RB1
|
doxorubicin hydrochloride • Kisqali (ribociclib)
Phase 2
Children's Oncology Group
Completed
Last update posted :
01/13/2022
Initiation :
10/12/2015
Primary completion :
06/30/2017
Completion :
09/30/2021
NCAM1
|
NCAM1 expression
|
lorvotuzumab mertansine (IMGN901)
Phase 1
Epizyme, Inc.
Completed
Last update posted :
12/27/2021
Initiation :
01/07/2016
Primary completion :
10/22/2021
Completion :
10/22/2021
SS18
|
SMARCA4 mutation
|
Tazverik (tazemetostat)
Phase 1
GlaxoSmithKline
Completed
Last update posted :
06/30/2021
Initiation :
09/27/2012
Primary completion :
06/18/2019
Completion :
06/18/2019
HLA-A • CTAG1B
|
HLA-A*02 • CTAG1B expression
|
cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
12/11/2019
Initiation :
03/01/2018
Primary completion :
03/01/2023
Completion :
03/01/2023
MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B
|
HLA-A*02:01 • CD19 expression • HLA-A positive
|
cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
11/12/2019
Initiation :
03/03/2000
Primary completion :
05/20/2009
Completion :
05/20/2009
CD34
|
CD34 positive
|
Neupogen (filgrastim)
Phase 1b/2a
GlaxoSmithKline
Withdrawn
Last update posted :
10/29/2019
Initiation :
02/25/2019
Primary completion :
07/18/2022
Completion :
07/18/2022
HLA-A • CTAG1B • CTAG2
|
HLA-A*02 • CTAG2 expression
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
12/11/2018
Initiation :
06/18/2012
Primary completion :
04/01/2014
Completion :
04/01/2014
mTOR • IR
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
Phase 1
Shenzhen Second People's Hospital
Unknown status
Last update posted :
08/03/2016
Initiation :
04/01/2015
Primary completion :
12/01/2019
Completion :
12/01/2019
CTAG1B
|
CTAG1B expression • HLA-A2 positive
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
Phase 1
Fred Hutchinson Cancer Center
Withdrawn
Last update posted :
02/03/2016
Initiation :
07/01/2014
Primary completion :
01/01/2016
Completion :
01/01/2016
CTAG1B
|
CTAG1B expression
|
cyclophosphamide • cyclophosphamide intravenous
Phase 1
Fred Hutchinson Cancer Center
Completed
Last update posted :
12/11/2014
Initiation :
01/01/2012
Primary completion :
09/01/2013
CTAG1B
|
CTAG1B expression
|
cyclophosphamide • cyclophosphamide intravenous